LY75-CD302

Across TCGA pan-cancer cohorts, LY75-CD302 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LY75-CD302 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LY75-CD302 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY75-CD302 expression acts as an unfavorable survival marker.

STAD are the cancer types where LY75-CD302 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.112	0.657	<.001	30	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LY75-CD302–STAD (DFS)

Open the STAD breakdown →